Novo Nordisk Aktie

Novo Nordisk für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 866931 / ISIN: US6701002056

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
12.10.2025 15:43:00

Should You Buy Novo Nordisk Right Now?

Wall Street analysts can't agree on Novo Nordisk (NYSE: NVO), with Morgan Stanley recently cutting its rating to underweight on the back of disappointing growth in key prescriptions in the U.S., and HSBC Holdings recently raising its rating to a buy on the strength of the potential of its pipeline. Who's right? The HSBC approach, in this case, may be sensible, at least on a risk-reward basis. The nearly 50% drop in Novo Nordisk shares is likely a reflection of the market's disappointment in Wegovy's (semaglutide) share loss in the weight loss market to Eli Lilly's Zepbound (tirzepatide).That said, the company has a few upcoming events that could return the stock to favor. First, it's leading the race to get an oral weight loss pill (oral Wegovy) approved and expects a decision from the FDA this year. Moreover, there's data to suggest superiority over Eli Lilly's candidate, orforglipron.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novo Nordisk 48,98 -3,38% Novo Nordisk
Novo Nordisk (spons. ADRs) 49,70 -1,97% Novo Nordisk (spons. ADRs)